Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10:472–84.

Article  CAS  PubMed  Google Scholar 

Alix-Panabières C, Pantel K. Real-time liquid biopsy: circulating tumor cells versus circulating tumor DNA. Ann Transl Med. 2013;1:18.

PubMed  PubMed Central  Google Scholar 

Schwarzenbach H. Circulating nucleic acids as biomarkers in breast cancer. Breast Cancer Res. 2013;15:211.

Article  PubMed  PubMed Central  Google Scholar 

Amir E, Ooi WS, Simmons C, et al. Discordance between Receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies. Clin Oncol. 2008;20:763–8.

Article  CAS  Google Scholar 

Bedard PL, Hansen AR, Ratain MJ, et al. Tumour heterogeneity in the clinic. Nature. 2013;501:355–64.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–48.

Article  CAS  PubMed  Google Scholar 

Lone SN, Nisar S, Masoodi T, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022;21:79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61:112–23.

Article  CAS  PubMed  Google Scholar 

Russano M, Napolitano A, Ribelli G, et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. J Exp Clin Cancer Res. 2020;39:95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim YJ, Cho Y-H, Min J, et al. Circulating tumor marker isolation with the chemically stable and instantly degradable (CSID) hydrogel immunospheres. Anal Chem. 2021;93:1100–9.

Article  CAS  PubMed  Google Scholar 

Heidrich I, Deitert B, Werner S, et al. Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors. Cancer Metastasis Rev. 2023;42:161–82.

Article  PubMed  PubMed Central  Google Scholar 

Seydack M. Nanoparticle labels in immunosensing using optical detection methods. Biosens Bioelectron. 2005;20:2454–69.

Article  CAS  PubMed  Google Scholar 

Roduner E. Size matters: why nanomaterials are different. Chem Soc Rev. 2006;35:583.

Article  CAS  PubMed  Google Scholar 

Wang C, Ye M, Cheng L, et al. Simultaneous isolation and detection of circulating tumor cells with a microfluidic silicon-nanowire-array integrated with magnetic upconversion nanoprobes. Biomaterials. 2015;54:55–62.

Article  CAS  PubMed  Google Scholar 

Park S, Wong DJ, Ooi CC, et al. Molecular profiling of single circulating tumor cells from lung cancer patients. Proc Natl Acad Sci USA. 2016;113:E8379–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lima-Oliveira G, Lippi G, Salvagno GL, et al. Laboratory diagnostics and quality of blood collection. J Med Biochem. 2015;34:288–94.

Article  PubMed  PubMed Central  Google Scholar 

Morris P, Perkins A. Diagnostic imaging. The Lancet. 2012;379:1525–33.

Article  Google Scholar 

Amri C, Shukla AK, Lee J-H. Recent advancements in nanoparticle-based optical biosensors for circulating cancer biomarkers. Materials. 2021;14:1339.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Chen D-S, Sung J-L. Serum alphafetoprotein in hepatocellular carcinoma. Cancer. 1977;40:779–83.

Article  CAS  PubMed  Google Scholar 

Ellis WJ, Blumenstein BA, Ishak LM, et al. Clinical evaluation of the BTA trak assay and comparison to voided urine cytology and the bard BTA test in patients with recurrent bladder tumors. Urology. 1997;50:882–7.

Article  CAS  PubMed  Google Scholar 

Fleuren GJ, Nap M, Aalders JG, et al. Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian tumors. Cancer. 1987;60:2437–42.

Article  CAS  PubMed  Google Scholar 

Humphris JL, Chang DK, Johns AL, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76:138–43.

Article  CAS  PubMed  Google Scholar 

Hsu Y-P, Hsieh C-H, Chien H-T, et al. Serum markers of CYFRA 21–1 and C-reactive proteins in oral squamous cell carcinoma. World J Surg Onc. 2015;13:253.

Article  Google Scholar 

Pattari SK, Dey P. Urine: beyond cytology for detection of malignancy. Diagn Cytopathol. 2002;27:139–42.

Article  PubMed  Google Scholar 

Cooper EH, Robinson MRG, Whelan P, et al. Tumor markers in prostate cancer. Cancer. 1992;70:225–9.

Article  CAS  PubMed  Google Scholar 

Burghuber OC, Worofka B, Schernthaner G, et al. Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer. Cancer. 1990;65:1386–90.

Article  CAS  PubMed  Google Scholar 

Ozeki I, Nakajima T, Suii H, et al. Analysis of hepatitis B surface antigen (HBsAg) using high-sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays. Hepatol Res. 2018;48:E263–74.

Article  CAS  PubMed  Google Scholar 

Tillmann HL. Hepatitis C virus core antigen testing: Role in diagnosis, disease monitoring and treatment. World J Gastroenterol. 2014;20:6701–6.

Article  PubMed  PubMed Central  Google Scholar 

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the spec. Eur J Heart Fail. 2016;18:891–975.

Article  PubMed  Google Scholar 

Zetterberg H, Wilson D, Andreasson U, et al. Plasma tau levels in Alzheimer’s disease. Alzheimers Res Ther. 2013;5:9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pilotto A, Parigi M, Bonzi G, et al. Differences between plasma and cerebrospinal fluid p-tau181 and p-tau231 in early Alzheimer’s disease. J Alzheimers Dis. 2022;87:991–7.

Article  CAS  PubMed  Google Scholar 

Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med. 2020;26:379–86.

Article  CAS  PubMed  Google Scholar 

Mehta PD, Pirttila T, Mehta SP, et al. Plasma and cerebrospinal fluid levels of amyloid 2Proteins 1–40 and 1–42 in Alzheimer disease. Arch Neurol. 2000;57:100–5.

Article  CAS  PubMed  Google Scholar 

Janelidze S, Stomrud E, Palmqvist S, et al. Plasma β-amyloid in Alzheimer’s disease and vascular disease. Sci Rep. 2016;6:26801.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer’ Dementia. 2017;13:841–9.

Article  Google Scholar 

Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. 2018;554:249–54.

Article  ADS  CAS  PubMed